Literature DB >> 12639305

In vivo quantitative noninvasive imaging of gene transfer by single-photon emission computerized tomography.

Alberto Auricchio1, Paul D Acton, Markus Hildinger, Jean-Pierre Louboutin, Karl Plössl, Erin O'Connor, Hank F Kung, James M Wilson.   

Abstract

Systems aimed at detecting gene expression noninvasively in vivo are desirable for evaluating the outcome of gene transfer in clinical trials. Several approaches have been exploited using magnetic resonance imaging and spectroscopy ((31)P MRS), positron emission tomography (PET), single-photon emission tomography (SPECT), and detection of bioluminescent signals. An ideal system is based on transfer of a marker gene, the activity of which can be detected against a background from the target tissue without interfering with normal physiology or eliciting an immune response. The majority of approaches described to date use genes encoding a nonmammalian protein that can elicit immune responses or a transmembrane receptor as a marker gene whose ectopic expression may cause aberrant signaling in the target cell through binding to endogenous ligands. The dopamine transporter (DAT) is normally expressed at high levels, mainly in the dopaminergic neurons of the central nervous system. We previously synthesized a radioactive ligand, [(99m)Tc]TRODAT-1, that binds with high affinity to the dopamine transporter, allowing for SPECT imaging of the striatum in normal control subjects and individuals affected with Parkinson's disease. Here we describe a strategy to monitor gene transfer based on adeno-associated viral vector (AAV)-mediated transduction of DAT in murine muscle followed by [(99m)Tc]TRODAT-1 imaging by SPECT of cells expressing the transgene. We show that quantitative, noninvasive imaging of gene transfer is successfully achieved in vivo, using a single-photon computed tomography camera. This system employs a reporter gene encoding a mammalian protein that is absent in most tissues, has no enzymatic activity, and does not activate intracellular pathways. This should be useful to monitor gene transfer in the settings of gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639305     DOI: 10.1089/10430340360535805

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  8 in total

Review 1.  Genetic engineered molecular imaging probes for applications in cell therapy: emphasis on MRI approach.

Authors:  In K Cho; Silun Wang; Hui Mao; Anthony Ws Chan
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-09-22

Review 2.  Imaging of cells and nanoparticles: implications for drug delivery to the brain.

Authors:  Katica Stojanov; Inge S Zuhorn; Rudi A J O Dierckx; Erik F J de Vries
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

Review 3.  Noninvasive cell-tracking methods.

Authors:  Moritz F Kircher; Sanjiv S Gambhir; Jan Grimm
Journal:  Nat Rev Clin Oncol       Date:  2011-09-27       Impact factor: 66.675

4.  Exercise rehabilitation for chronic heart failure patients with cardiac device implants.

Authors:  Robert G Haennel
Journal:  Cardiopulm Phys Ther J       Date:  2012-09

5.  Performance evaluation of small-animal multipinhole μSPECT scanners for mouse imaging.

Authors:  Steven Deleye; Roel Van Holen; Jeroen Verhaeghe; Stefaan Vandenberghe; Sigrid Stroobants; Steven Staelens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-24       Impact factor: 9.236

6.  Quantitative imaging of myocardial infarct in rats with high resolution pinhole SPECT.

Authors:  Paul D Acton; Daniel Thomas; Rong Zhou
Journal:  Int J Cardiovasc Imaging       Date:  2006-03-04       Impact factor: 2.357

Review 7.  Seeing stem cells at work in vivo.

Authors:  Amit K Srivastava; Jeff W M Bulte
Journal:  Stem Cell Rev Rep       Date:  2014-02       Impact factor: 5.739

8.  Camelid reporter gene imaging: a generic method for in vivo cell tracking.

Authors:  Lode Ry Goethals; Tomas J Bos; Luc Baeyens; Frank De Geeter; Nick Devoogdt; Tony Lahoutte
Journal:  EJNMMI Res       Date:  2014-06-26       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.